New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
05:51 EDTACT, PFE, VRX, MYLPfizer's generics unit attracts several suitors, Reuters reports
Valeant Pharmaceuticals (VRX), Actavis (ACT) and Mylan (MYL) are each interested in buying Pfizer's (PFE) branded generics business, sources say, even though there are no ongoing discussions at this point, reports Reuters.Reference Link
News For VRX;ACT;MYL;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
November 11, 2014
16:24 EDTVRXOn The Fly: Closing Wrap
Subscribe for More Information
15:46 EDTVRXPershing Square, Sachem Head build 10% stake in Zoetis, WSJ reports
Subscribe for More Information
15:43 EDTPFELeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:32 EDTACT, VRXValeant likely to raise offer for Allergan again, says Bernstein
Subscribe for More Information
November 10, 2014
16:34 EDTACTActavis appoints Maria Teresa Hilado as CFO
Subscribe for More Information
November 9, 2014
13:26 EDTVRXAckman's Allergan court win may prove costly down the road, Bloomberg says
When U.S. District Court Judge David Carter ruled on November 4 that Pershing Square can vote its 9.7% stake in Allergan (AGN) in a shareholder ballot aiming to remove Allergan directors, he also noted that there were “serious questions” regarding insider trading rules in the way Pershing Square acquired Allergan stock while preparing a bid with Valeant (VRX), says Bloomberg. Reference Link
November 7, 2014
17:05 EDTVRXValeant sends open letter to physician customers
Subscribe for More Information
14:56 EDTVRXAllergan says Valeant offers to date inadequate, would consider increased bid
Subscribe for More Information
09:49 EDTVRX, ACTAckman says Allergan 'tipping scales' in Actavis’ favor, disadvantaging Valeant
Subscribe for More Information
08:01 EDTMYLMylan signs alliance agreement with Disney Parks to enhance EpiPen access
Subscribe for More Information
November 6, 2014
10:30 EDTVRX, ACTAllergan disclosure today forced by SEC, CNBC's Faber reports
Subscribe for More Information
10:05 EDTACTActavis talks to buy Salix put on hold, Bloomberg says
Subscribe for More Information
09:36 EDTPFEGlycoMimetics announces presentation of GMI-1271, rivipansel
Subscribe for More Information
09:28 EDTVRX, ACTActavis in active talks to acquire Allergan, Bloomberg reports
Actavis (ACT) is in active talks to acquire Allergan (AGN), Bloomberg reports, citing sources. Allergan earlier today disclosed in a filing that it has been approached by another party and that talks "may lead to negotiations." Shares of Allergan are up 1.1% to $198.50 in pre-open trading while Actavis is up 1% to $250.07. Valeant (VRX) is down 1.8% to $129.58. Reference Link
09:24 EDTACT, VRXActavis in active talks to acquire Allergan, Bloomberg reports
Subscribe for More Information
09:22 EDTACTActavis price target raised to $290 from $270 at Susquehanna
Subscribe for More Information
09:06 EDTVRX, ACTAllergan says approach may lead to merger negotiations
Allergan (AGN) disclosed in new regulatory filing, “Notwithstanding the foregoing, we have been approached by another party regarding a potential merger transaction. Discussions between us and that party have continued and may lead to negotiations.” It has been reported that the unnamed party is Actavis (ACT). Allergan is attempting to fend off a hostile takeover by Valeant (VRX).
07:54 EDTACTActavis pipeline remains under-appreciated, says UBS
Subscribe for More Information
07:52 EDTACTActavis price target raised to $290 from $260 at Leerink
Subscribe for More Information
06:35 EDTPFEAstraZeneca CEO says tax revisions cripple new Pfizer offer, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use